Amarin Corp Plc (AMRN)

[lettruthringout]

The likely strength of MITIGATE trial ...

... lies not in its Primary Outcomes or even its Secondary Outcomes, but rather in its tertiary outcome measures. If you put 2000+ people at cardiovascular risk on Vascepa and compare them on the below measures with a similar group not on Vascepa over a 6-month time frame, I believe it is likely that there will be significant differences among these measures. That would be a win for Vascepa independent of the viral URI data. And there was after all, 5 times as much MACE incidence already in the combined groups shown in June presentation as there was mod-severe viral URI (and twice as many hospitalization in combined groups for worsening heart failure hospitalizations as there was incidence of mod-severe viral URI).

Other Outcome Measures:

1. Percentage of participants who die due to any cause [ Time Frame: 0-12 months ]

2. Percentage of participants experiencing a major adverse cardiovascular event [ Time Frame: 0-12 months ]
Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke

3. Percentage of participants experiencing an expanded major adverse cardiovascular event [ Time Frame: 0-12 months ]
Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)

4. Percentage of participants who are hospitalized for heart failure [ Time Frame: 0-12 months ]

5. Percentage of participants who are hospitalized for any reason [ Time Frame: 0-12 months ]

6. Percentage of participants who have an emergency department visit for any reason [ Time Frame: 0-12 months ]